CLINICAL TRIALS PROFILE FOR NASACORT HFA

All Clinical Trials for NASACORT HFA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00132925 ↗	An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis	Completed	Sanofi	Phase 3	2003-11-01	The purposes of this study are: - To demonstrate the efficacy of once daily administration of Nasacort AQ 110 µg compared with placebo in children 2-5 years of age with perennial allergic rhinitis; and - To assess the safety of Nasacort AQ 110 µg in children 2-5 years of age.
NCT00344942 ↗	Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults	Terminated	Sanofi	Phase 3	2006-04-01	To demonstrate the superiority of the clinical efficacy of 12 weeks' treatment with Nasacort versus placebo in adult patients presenting with Chronic Non Allergic and Non Infectious Rhinitis
NCT00449072 ↗	Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)	Completed	Sanofi	Phase 4	2007-03-01	The primary objective of the study was to characterize the difference in prepubescent growth velocity in children 3 to 9 years of age with perennial allergic rhinitis (PAR) treated with triamcinolone acetonide (TAA) nasal spray (NASACORT® AQ 110 μg treatment group) or placebo (NASACORT® AQ placebo group) for 12-months. The secondary objectives were to compare the following in prepubertal participants treated with TAA nasal spray versus placebo: - the 24-hour urinary free cortisol levels and the cortisol/creatinine ratio (to measure the Hypothalamic-Pituitary Adrenal [HPA] axis function) - the rate of treatment-emergent-adverse-events (TEAE) - global efficacy rated by the investigator and the participant separately - the rate of use of rescue medication during the study
NCT00987233 ↗	A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis	Completed	Apotex Inc.	Phase 3	1969-12-31	A randomized, double-blind, placebo-controlled parallel-group study, comparing the bioequivalence of triamcinolone acetonide aqueous nasal spray (Apotex, Inc.) to that of Nasacort® AQ nasal spray (Sanofi-Aventis Pharmaceutical Products, Inc.) in the treatment of seasonal allergic rhinitis.
NCT01154153 ↗	Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis	Completed	Sanofi	Phase 4	2010-06-01	The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 μg) and TAA-AQ (220 μg) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA) axis function as measured by serum cortisol AUC(0-24 hr) in children (>=2 to
NCT02877485 ↗	The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation	Completed	Stanford University	Phase 4	2016-08-01	The purpose of this project is to determine if intranasal corticosteroids have an effect on nasal obstruction in patients with nasal septal deviation.
NCT03317015 ↗	A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)	Completed	Sanofi	Phase 3	2016-11-30	Primary Objective: - To assess efficacy of Nasacort® (triamcinolone) nasal spray, 55 µg per dose, in comparison with Flixonase® (fluticasone) nasal spray, 50 µg per dose, by reflective total nasal symptom score (rTNSS) (24 h) after 28 days of treatment compared with baseline (0 day of treatment) in adult patients suffering from PAR (perennial allergic rhinitis). Secondary Objectives: - To evaluate safety of Nasacort® (triamcinolone) nasal spray, in comparison with Flixonase® (fluticasone) administered for 28 days by assessment of adverse events reports. - To evaluate patient and physician satisfaction after 28 days of treatment by 5-point scale. - To estimate improvement of quality of life during the study by mini Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ).

Clinical Trial Conditions for NASACORT HFA

Condition Name

Condition Name for NASACORT HFA
Intervention	Trials
Rhinitis, Allergic, Perennial	2
Seasonal Allergic Rhinitis	1
Allergic Asthma	1
Nasal Obstruction	1

Condition MeSH

Condition MeSH for NASACORT HFA
Intervention	Trials
Rhinitis	6
Rhinitis, Allergic	5
Rhinitis, Allergic, Perennial	4
Nasal Obstruction	1

Clinical Trial Locations for NASACORT HFA

Trials by Country

Trials by Country for NASACORT HFA
Location	Trials
United States	12
Canada	1
France	1

Trials by US State

Trials by US State for NASACORT HFA
Location	Trials
New Jersey	3
California	2
South Carolina	1
North Carolina	1
Nebraska	1

Clinical Trial Progress for NASACORT HFA

Clinical Trial Phase

Clinical Trial Phase for NASACORT HFA
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	4
N/A	1

Clinical Trial Status

Clinical Trial Status for NASACORT HFA
Clinical Trial Phase	Trials
Completed	6
Terminated	1
Unknown status	1

Clinical Trial Sponsors for NASACORT HFA

Sponsor Name

Sponsor Name for NASACORT HFA
Sponsor	Trials
Sanofi	5
Apotex Inc.	1
Stanford University	1

Sponsor Type

Sponsor Type for NASACORT HFA
Sponsor	Trials
Industry	6
Other	2

NASACORT HFA Market Analysis and Financial Projection

Last updated: May 1, 2026

Nasacort HFA (triamcinolone acetonide) clinical trials update and market analysis with projections

What is Nasacort HFA and how is it used clinically?

Nasacort HFA is a pressurized metered-dose inhaler formulation of triamcinolone acetonide indicated for treatment of seasonal and perennial allergic rhinitis in the US. It is the same active molecule (triamcinolone acetonide) as other Nasacort products; the distinction is the delivery system (HFA vs other formulations). FDA labeling describes intranasal dosing schedules based on age and rhinitis type. FDA prescribing information is the authoritative source for indications, dosing, and key safety language. [1]

---

What is the current clinical-trials update for Nasacort HFA?

No complete, definitive “phase-by-phase” update for Nasacort HFA can be issued without a conflict risk between the product monograph and study-level identifiers. The public record most reliably supports the following status signals:

• Nasacort HFA is an established, marketed product with FDA-approved labeling and no widely visible, late-stage (registrational) program under the Nasacort HFA brand in public registries in the last reporting cycle.
• Public clinical-trials activity for intranasal triamcinolone and HFA-based delivery platforms typically concentrates on:
  • formulation equivalence and device/bioavailability work,
  • comparative studies across intranasal steroids for allergic rhinitis endpoints,
  • pediatric and adherence or real-world effectiveness studies.

The evidence base that drives clinical uptake is long-standing efficacy data for intranasal corticosteroids in allergic rhinitis, with Nasacort HFA as a branded option within that class. FDA labeling remains the main reference point for dosing and expected outcomes. [1]

---

How does the market define Nasacort HFA’s competitive set?

Nasacort HFA competes in the allergic rhinitis (AR) category within intranasal corticosteroids (INCS). The competitive set used by manufacturers, payers, and formularies is usually framed by:

• Intranasal corticosteroids (class peers)
• Allergic rhinitis symptom controllers, including antihistamines and combination therapies where used
• payer channel behavior that drives switch activity toward lower net-cost options

In the US, brand intranasal steroids face margin pressure from:

• generic versions of active molecules in the INCS class,
• formulary preference for specific devices (sprays) with cost advantages,
• step therapy practices.

FDA labeling supports that Nasacort HFA is positioned as an AR controller via intranasal corticosteroid activity. [1]

---

What is the market outlook for allergic rhinitis intranasal steroids?

Allergic rhinitis remains a chronic or recurrent condition treated long-term by many patients. The market for INCS is supported by:

• persistent prevalence in adults and children,
• seasonal and perennial symptom cycles,
• high treatment adherence for those who respond to intranasal steroids,
• ongoing payer efforts to control cost through step edits and generic substitution.

For business planning, the most decision-relevant driver is not “medical need,” it is net pricing and channel access as generics and authorized equivalents capture share.

Nasacort HFA’s commercial trajectory should be modeled as:

• stable-to-declining unit share for remaining brand inventory,
• resilience of prescription share where dosing convenience and physician preference offset cost switching,
• erosion to generic triamcinolone acetonide intranasal equivalents and other INCS where formulary design favors them.

This category-level framework is consistent with how INCS product families perform post-generic entry and with the continued central role of FDA-approved labeled use for AR. [1]

---

What does a practical projection model look like for Nasacort HFA?

A rigorous projection requires current unit/price baselines and payer-level net-price estimates. Those inputs are not provided here, so the projection is confined to a scenario structure built for decision-making that maps to how INCS brands typically underperform once generic substitution dominates.

Use a share-and-net-revenue projection approach:

1. Prescription volume trends with category growth (modest) minus brand share erosion (faster).
2. Net pricing trends down with payer and pharmacy switch dynamics.
3. Inventory and channel effects produce short-lived deviations around generic price resets.

A working structure for financial modeling:

Projection lever	Direction for an established AR INCS brand	Primary mechanism
Unit share	Down	Generic and formulary substitution in INCS class
List-to-net	Down	Discounting and payer contracting pressure
Category growth passthrough	Limited	INCS remains used, but share shifts away from brands
Device loyalty impact	Mild	HFA delivery can support adherence for some prescribers/patients
Time horizon effect	Cumulative	Multiple switch waves through formulary updates

Clinical dosing and safety parameters from FDA labeling are unchanged planning anchors for use patterns and expected adherence behavior. [1]

---

What is the regulatory and labeling baseline for dosing and use?

FDA labeling defines product characteristics that matter for payer and clinical experience:

• Indication: allergic rhinitis (seasonal and perennial) treatment in the US. [1]
• Route: intranasal.
• Dosage: age-based dosing schedule described in labeling; it is central for forecasting prescription counts per patient-year and dosing compliance assumptions. [1]

These items are the input layer for any “patients treated” projection because AR treatment intensity in INCS is largely dosing-driven.

---

What are the key clinical endpoint benchmarks for market differentiation?

INCS differentiation in AR is usually less about fundamentally different efficacy than about:

• onset characteristics,
• symptom control consistency across seasons,
• tolerability and adherence factors tied to device and spray technique,
• patient preference and physician familiarity.

Nasacort HFA’s claim set and dosing are reflected in FDA labeling. [1]

---

What is the investment-grade implication for Nasacort HFA?

Given Nasacort HFA’s established status and the standard post-generic competitive dynamics in INCS AR:

• The near-term strategic focus is typically on defending net revenue rather than expanding through new mechanism differentiation.
• Growth opportunities, where they exist, come from channel execution, formulary positioning, and patient retention within the intranasal steroid controller class.

This is consistent with the continued centrality of FDA-labeled dosing for AR management. [1]

---

Key Takeaways

• Nasacort HFA is an established FDA-labeled intranasal triamcinolone acetonide product for seasonal and perennial allergic rhinitis. [1]
• Public-facing clinical-trials activity is not aligned to an obvious late-stage registrational update for Nasacort HFA as a standalone brand program; the evidence base is driven by labeled efficacy and longstanding INCS practice. [1]
• Market outlook is dominated by INCS class dynamics: generic substitution and formulary step strategies compress brand share and net pricing over time.
• Projection modeling should use a share-and-net revenue framework with cumulative brand erosion as the dominant variable, moderated by dosing/device loyalty.

---

FAQs

1) What condition does Nasacort HFA treat?

Nasacort HFA treats seasonal and perennial allergic rhinitis. [1]

2) What active ingredient is in Nasacort HFA?

The active ingredient is triamcinolone acetonide. [1]

3) Is Nasacort HFA used as a controller therapy?

Yes. It is used for treatment of allergic rhinitis, with dosing defined in the FDA label. [1]

4) What endpoints matter most for competitive differentiation in allergic rhinitis INCS?

Competitive positioning typically hinges on symptom control consistency and tolerability/adherence, anchored to FDA labeling and clinical practice endpoints used across AR trials. [1]

5) How should investors model Nasacort HFA over a multi-year horizon?

Model brand unit share erosion and net price compression as primary drivers, using FDA label dosing to map prescriptions to patient-years. [1]

---

References

[1] U.S. Food and Drug Administration. (n.d.). Nasacort HFA prescribing information (triamcinolone acetonide). FDA. https://www.accessdata.fda.gov/ (access via the current Nasacort HFA label page)